To include your compound in the COVID-19 Resource Center, submit it here.

Now It's Up to NicOx

Following seven months of wrangling over AZD3582, AstraZeneca plc and NicOx S.A. finally got a divorce last week. The pharma company decided not to move AZD3582 into Phase III trials to treat osteoarthritis

Read the full 338 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE